You are here: Home » Companies » News
Business Standard

Syngene, 3DC ink pact for advancing therapeutic discovery projects

Syngene International on Thursday said it has signed an agreement with Deerfield Discovery and Development Corporation (3DC)to collaborate for five years to advance therapeutic discovery projects.

Topics
Syngene

Press Trust of India  |  New Delhi 

Syngene
Syngene | Photo: Website of Syngene

International on Thursday said it has signed an agreement with Deerfield Discovery and Development Corporation (3DC)to collaborate for five years to advance therapeutic discovery projects.

The collaboration is to advance the therapeutic discovery projects from target validation through to pharmacological proof of concept and pre-clinical evaluation, said in a statement.

"will deliver fully integrated therapeutic discovery programs for 3DC...Their reputation for identifying highly promising science is a great fit with our ability to lead and deliver world-class scientific execution for their growing portfolio," Syngene MD and CEO Jonathan Hunt said.

3DC has selected Syngene as a key execution partner for a developing portfolio of molecular entities, spanning multiple therapeutic areas and modalities, the statement said.

"This collaboration forms an important part of our execution strategy. When we identify a promising biological target, our goal is to discover and deliver the best possible therapeutic agent to the clinic as quickly and safely as possible.

"We believe the Syngene-Deerfield collaboration may provide critical new therapeutic options with pace and efficiency that could improve the lives of many patients," 3DC CEO Mike Foley said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 19 2020. 20:43 IST
RECOMMENDED FOR YOU
.